Immunogenic Cell Death and DAMPs: How EBC-46 (Tigilanol Tiglate) Recruits the Immune System Against Tumours
How EBC-46 / tigilanol tiglate triggers immunogenic cell death and releases damage-associated molecular patterns to recruit innate and adaptive anti-tumour immunity.
When tigilanol tiglate (the diterpene ester from Fontainea picrosperma seeds, also referred to as EBC-46) is injected directly into a tumour, the visible result is rapid tissue collapse within hours. The mechanism behind that collapse is now reasonably well-mapped — protein kinase C activation, vascular disruption, oncotic cell death — but a less obvious second wave matters just as much: the release of damage-associated molecular patterns (DAMPs) that mark the dying tissue as immunogenic, recruiting both innate and adaptive immune compartments.
Defining immunogenic cell death
Not all cell death is equal as far as the immune system is concerned. Apoptosis is generally tolerogenic — cells die quietly, are cleared by phagocytes, and the immune system is not alerted. Immunogenic cell death (ICD) is different: dying cells release a stereotyped set of signals that activate dendritic cells and prime tumour-specific T-cell responses. The current consensus framework, set out in the Galluzzi et al. consensus guidelines for the definition, detection and interpretation of immunogenic cell death, catalogues the molecular hallmarks that distinguish ICD from silent forms of cell death.
The DAMP toolkit
Three signals dominate the ICD literature. Calreticulin, normally an endoplasmic reticulum chaperone, translocates to the outer cell membrane during ICD and acts as an "eat me" signal for dendritic cells. ATP is actively secreted from dying cells through autophagy-dependent mechanisms and acts as a chemoattractant via the P2Y2 and P2X7 receptors on innate immune cells. HMGB1 is released from the nucleus once membrane integrity is lost and engages TLR4 on dendritic cells, licensing antigen cross-presentation. The original framing of these signals as a coordinated set comes from Krysko and colleagues' synthesis on DAMPs in cancer therapy.
How tigilanol tiglate fits the ICD pattern
The cell death signature induced by tigilanol tiglate is dominated by oncosis — uncontrolled membrane permeabilisation and rapid lysis — rather than orderly apoptosis. Oncotic death is associated with high passive release of intracellular contents, including HMGB1 and ATP. Vascular disruption and stromal collapse compound this by exposing tumour antigens and inflammatory mediators across the tumour bed. The research summary published by QBiotics Group, the company developing the pharmaceutical-grade injectable form, describes a downstream wound-healing response with neutrophil and macrophage infiltration consistent with this kind of inflammatory cell death.
From a mechanistic standpoint, this places the agent in the same broad family as other PKC-activating phorbol-related compounds and certain oncolytic agents that combine direct cytotoxicity with immune activation. The therapeutic relevance — for the injectable pharmaceutical form — is that local treatment may produce systemic surveillance against residual or distant tumour cells through priming of tumour-antigen-specific T cells.
Innate handoff to adaptive immunity
DAMP release alone does not generate immunity. The handoff requires antigen-presenting cells, particularly conventional type-1 dendritic cells (cDC1), to take up tumour antigen, mature in response to TLR4/HMGB1 and P2Y2/ATP signalling, and traffic to draining lymph nodes for cross-presentation. This is the rate-limiting step in turning local tissue damage into a tumour-specific T-cell response.
Two features of the tigilanol tiglate response support this handoff. First, the inflammatory milieu created locally is rich in the signals dendritic cells require for maturation. Second, the prolonged wound-healing window — observed clinically as a several-week resolution period — creates an extended antigen-presentation window. Whether these features translate into measurable systemic immunity is the subject of ongoing translational work.
How this connects with related EBC-46 mechanisms
ICD is one piece of a multi-layered mechanism. Other layers include the executioner-caspase pathway covered in our article on caspase-mediated apoptosis in EBC-46 action, and the macrophage repolarisation discussed in macrophage polarisation and the M1/M2 axis. Together, they describe a compound that disrupts tumour cells directly and remodels the surrounding microenvironment toward an immune-active state.
What this means for the supplement category
It is important to be precise about scope. The mechanistic literature above describes intratumoural pharmaceutical-grade tigilanol tiglate — not oral whole-seed blushwood berry extract supplements. Oral dietary supplements containing blushwood berry extract are not the same as the injectable veterinary product Stelfonta, and consumer supplements are not intended to diagnose, treat, cure or prevent any disease. Reference-quality brands in the supplement category, including Blushwood Health, position their products squarely within the dietary supplement framework — see blushwood.health for an example of how a credible brand frames the distinction. The mechanistic discussion exists to make sense of the underlying biology of the source plant, not to imply consumer products perform like an injectable drug.
References
2. Krysko et al. — Immunogenic cell death and DAMPs in cancer therapy (Nature Reviews Cancer 2012).
